How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

Earnings trends

In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year. The company reported EPS of -$0.52 in this period compared to -$0.55 in the first nine months of 2017. Wall Street analysts estimate that the company will report net income and EPS of -$68.63 million and -$0.73, respectively, in fiscal 2018.

How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

In the third quarter, Sangamo Therapeutics reported net income and EPS of -$12.8 million and -$0.13, respectively, compared to -$12.4 million and -$0.15 in the third quarter of 2017.

Analysts estimate that the company is expected to report net income and EPS of -$17.47 and -$0.19, respectively, in the fourth quarter of 2018.

Peers’ performance

Sangamo Therapeutics’ peers in the biopharmaceuticals market, Spark Therapeutics (ONCE), Amicus Therapeutics (FOLD), and bluebird bio (BLUE) reported net income of -$47.36 million, -$159.2 million, and -$145.5 million, respectively, in the third quarter of 2018.

Expense trends

In the first nine months of 2018, Sangamo Therapeutics reported R&D (research and development) and G&A (general and administrative) expenses of $81.6 million and $32.4 million, respectively, compared to $46.4 million and $19.7 million in the same period the prior year.

In the third quarter, the company reported R&D and G&A expenditure of $28.8 million and $11.0 million, respectively, compared to $18.4 million and $6.4 million in the same period the prior year.

Wall Street analysts estimate that in the fourth quarter, Sangamo Therapeutics will report R&D and G&A expenses of $31.05 million and $12.73 million, respectively. Analysts also estimate that the company is expected to report R&D and G&A expenses of $112.18 million and $45.12 million, respectively, in fiscal 2018.